Esmopex-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75mg and Esomeprazole 40mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief and promoting healing in acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation of Esmopex-L ensures prolonged therapeutic plasma concentrations, optimizing efficacy and improving patient compliance through once-daily dosing. This combination is particularly beneficial in patients presenting with overlapping symptoms of acid reflux and impaired gastric motility. Esmopex-L Capsule SR should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, severe hepatic or renal impairment, and those on concomitant medications that may interact with dopamine antagonists or proton pump inhibitors. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic outcomes and minimize potential adverse effects.